NCT00317772 - Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 2, 2004

Primary Completion Date

November 4, 2020

Study Completion Date

November 4, 2020

Conditions

Ovarian CancerPeritoneal NeoplasmsFallopian Tube Cancer

Interventions

DRUG

Topotecan

"Phase I Starting Dose: 2 mg/m\^2 by vein Weekly Over 30 Minutes on Days 1, 8, and 15.~Phase II: MTD dose from Phase I by vein weekly on Days 1, 8, and 15."

DRUG

Gefitinib

"Phase I: 250 mg by mouth daily for 28 Days.~Phase II: 250 mg by mouth daily for 28 Days."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston